Shattuck Labs implements a digital transformation strategy by centralizing its clinical trial data management. They leverage specialized systems to oversee Contract Research Organization (CRO) activities from electronic Case Report Form (eCRF) design to data validation. This approach makes their development process specific by integrating external data sources directly into internal data workflows.
This transformation makes clinical data, external system integrations, and regulatory compliance processes critical. The reliance on external CROs and diverse data inputs introduces risks of data discrepancies and compliance gaps. This page analyzes key initiatives and operational challenges within Shattuck Labs’s digital transformation.
Shattuck Labs Snapshot
Headquarters: Austin, United States
Number of employees: 11-50 employees
Public or private: Public
Business model: B2B
Website: http://www.shattucklabs.com
Shattuck Labs ICP and Buying Roles
Shattuck Labs sells to clinical-stage biotechnology companies with complex drug development pipelines requiring rigorous data governance. They also target organizations that heavily rely on outsourced clinical research operations.
Who drives buying decisions
- Chief Medical Officer → Oversees clinical development strategy and trial execution
- Head of R&D → Manages research portfolio and scientific innovation
- VP of Clinical Operations → Directs clinical trial conduct and vendor management
- Director of Data Management → Ensures clinical data integrity and compliance
- Head of Regulatory Affairs → Manages regulatory submissions and adherence
- Chief Scientific Officer → Leads scientific discovery and technology adoption
Key Digital Transformation Initiatives at Shattuck Labs (At a Glance)
- Centralizing Clinical Data Oversight: Managing eCRF design, database development, and validation activities by Contract Research Organizations.
- Integrating External Clinical Data: Reconciling data from central laboratories, imaging vendors, and ePRO/eCOA systems.
- Advancing Biologics Engineering: Designing novel DR3-targeting antibodies using advanced protein engineering techniques.
- Streamlining Clinical Trial Reporting: Aggregating Phase 1 clinical data for safety, pharmacokinetics, and receptor occupancy disclosures.
- Optimizing R&D Portfolio: Refocusing research and development efforts by discontinuing oncology programs to prioritize specific immunology pipelines.
Where Shattuck Labs’s Digital Transformation Creates Sales Opportunities
| Vendor Type | Where to Sell (DT Initiative + Challenge) | Buyer / Owner | Solution Approach |
|---|---|---|---|
| Clinical Data Management Platforms | Centralizing Clinical Data Oversight: CRO eCRF design does not align with internal data standards before database build. | Director of Data Management, VP of Clinical Operations | Standardize eCRF templates and data capture rules before system deployment. |
| Integrating External Clinical Data: Data discrepancies arise between central laboratory data and ePRO system inputs. | Director of Data Management, Head of Biostatistics | Validate incoming data against predefined quality checks before integration into central database. | |
| Streamlining Clinical Trial Reporting: Manual data reconciliation delays report generation for regulatory submissions. | Head of Regulatory Affairs, Chief Medical Officer | Consolidate clinical data from disparate sources for automated report assembly. | |
| Biologics Discovery Software | Advancing Biologics Engineering: Computational models predict antibody binding, but wet lab validation fails repeatedly. | Head of R&D, Chief Scientific Officer | Enhance in-silico prediction accuracy of antibody-target interactions before synthesis. |
| Advancing Biologics Engineering: Experimental data from high-throughput screening lacks consistent metadata for analysis. | Head of R&D, Principal Scientist | Standardize data capture and annotation for all experimental outputs during discovery phases. | |
| R&D Project Management Tools | Optimizing R&D Portfolio: Resource allocation does not align with strategic pipeline refocus decisions. | Head of R&D, Chief Financial Officer | Route project proposals for resource approval based on updated portfolio priorities. |
| Optimizing R&D Portfolio: Actual R&D spending exceeds budget due to inaccurate real-time cost tracking. | Chief Financial Officer, Head of R&D | Track project-level expenditures against budget allocations in real time. | |
| Regulatory Compliance & QA Systems | Centralizing Clinical Data Oversight: CRO audit trails do not consistently meet 21 CFR Part 11 requirements. | Head of Regulatory Affairs, Director of Data Management | Enforce electronic record-keeping and signature protocols across all clinical data operations. |
| Integrating External Clinical Data: External data transfers lack proper validation checks for audit readiness. | Head of Regulatory Affairs, VP of Clinical Operations | Validate data transfer integrity and security against regulatory guidelines before system ingestion. |
Identify when companies like Shattuck Labs are in-market for your solutions.
Spot buying signals, find the right prospects, enrich your data, and reach out with relevant messaging at the right time.
What makes this Shattuck Labs’s digital transformation unique
Shattuck Labs prioritizes digital transformation within its core scientific development processes rather than general business functions. They heavily depend on integrating diverse external clinical data with internal systems for robust regulatory compliance and scientific advancement. This makes their transformation complex, requiring precise data interoperability and oversight, especially with outsourced clinical research organizations. Their specific focus on advanced protein engineering for novel therapeutics also drives a unique need for specialized computational and data management tools in early-stage R&D.
Shattuck Labs’s Digital Transformation: Operational Breakdown
DT Initiative 1: Centralized Clinical Data Oversight
What the company is doing
Shattuck Labs establishes a central framework to oversee all data management activities performed by its Contract Research Organizations. This includes standardizing eCRF design, developing databases, and defining data validation processes. They review and approve all CRO data management documents before implementation.
Who owns this
- Director of Data Management
- VP of Clinical Operations
- Head of Regulatory Affairs
Where It Fails
- eCRF design from CROs does not consistently capture required data points for specific regulatory filings.
- Database development by external vendors fails to integrate seamlessly with existing internal analytics platforms.
- Data validation rules executed by CROs do not detect all logical inconsistencies across study sites.
- Data Management Plans from CROs omit critical steps for data reconciliation with external sources.
- Database lock activities face delays when unaddressed queries remain open in the Electronic Data Capture system.
Talk track
Noticed Shattuck Labs centralizes clinical data oversight for CRO activities. Been looking at how some biotech teams standardize eCRF design and data validation rules upfront instead of fixing issues later, can share what’s working if useful.
DT Initiative 2: Integrating External Clinical Data
What the company is doing
Shattuck Labs manages the reconciliation and integration of diverse external data sources, including central laboratories, imaging vendors, and electronic Patient-Reported Outcome (ePRO) systems. They ensure these external data transfers are complete, timely, and meet predefined data quality standards. This process maintains compliance with internal data management standards.
Who owns this
- Director of Data Management
- Head of Biostatistics
- VP of Clinical Operations
Where It Fails
- External laboratory data files contain inconsistent formatting that blocks automated ingestion into the clinical database.
- Imaging vendor data transfers arrive without proper patient identifiers, requiring manual mapping.
- ePRO system data exhibits missing time points for patient entries, creating gaps in longitudinal analysis.
- External data transfer specifications from CROs do not account for all data fields required by internal reporting.
- Reconciliation processes between external data streams and eCRF data require significant manual intervention.
Talk track
Saw Shattuck Labs integrates external clinical data from various sources. Been looking at how some teams validate incoming data against quality checks automatically instead of manually reconciling discrepancies, happy to share what we’re seeing.
DT Initiative 3: Advancing Biologics Engineering
What the company is doing
Shattuck Labs develops novel DR3-targeting antibodies using advanced protein engineering capabilities. This involves designing bispecific antibodies and conducting preclinical studies to demonstrate superior inhibition and efficacy. They advance lead candidates like SL-325 from preclinical stages into clinical development.
Who owns this
- Head of R&D
- Chief Scientific Officer
- Principal Scientist
Where It Fails
- Computational protein design models generate candidate antibodies that fail to show desired activity in initial in vitro assays.
- Experimental data from early-stage screening systems does not connect directly to protein design software for iterative optimization.
- Preclinical data for novel bispecific antibodies lacks standardized reporting, slowing down comparative analysis.
- Development pipelines produce antibody constructs that exhibit stability issues during scale-up for preclinical testing.
- Design modifications for Fc-silencing in monoclonal antibodies result in unexpected off-target binding in subsequent tests.
Talk track
Looks like Shattuck Labs advances biologics engineering for DR3-targeting antibodies. Been seeing how some R&D teams enhance in-silico prediction accuracy before costly wet lab synthesis, can share what’s working if useful.
DT Initiative 4: Optimizing R&D Portfolio
What the company is doing
Shattuck Labs strategically optimizes its research and development portfolio by refocusing efforts on specific immunology pipelines. They discontinued oncology programs to prioritize lead candidates like SL-325. This involves reallocating resources and managing R&D expenses to align with the updated strategic direction.
Who owns this
- Chief Financial Officer
- Head of R&D
- Chief Executive Officer
Where It Fails
- Budget allocations for R&D projects do not update quickly after strategic pipeline refocus decisions.
- Project tracking systems fail to provide granular cost data for specific preclinical activities.
- Resource forecasting for scientific personnel does not adjust accurately to shifting portfolio priorities.
- Manual reporting of R&D expenditures makes it difficult to assess real-time burn rates against project budgets.
- Decision-making frameworks for pipeline prioritization lack real-time financial and scientific performance data.
Talk track
Noticed Shattuck Labs optimizes its R&D portfolio by refocusing pipelines. Been looking at how some biopharma teams track project-level expenditures against budget allocations in real time instead of relying on delayed reports, happy to share what we’re seeing.
Who Should Target Shattuck Labs Right Now
This account is relevant for:
- Clinical Data Management Software vendors
- Biologics Discovery and Design Platforms
- R&D Project and Portfolio Management Systems
- Regulatory Compliance and Quality Assurance Software
- Data Integration and Interoperability Solutions
- Advanced Analytics for Clinical Trials
Not a fit for:
- Basic CRM software without clinical research capabilities
- Generic IT infrastructure providers without biotech specialization
- Standard HR or payroll systems
- Marketing automation platforms
- Retail analytics solutions
When Shattuck Labs Is Worth Prioritizing
Prioritize if:
- You sell solutions that standardize eCRF design and data validation rules for CRO oversight.
- You sell platforms that validate incoming external clinical data against predefined quality checks before integration.
- You sell tools that consolidate clinical data from disparate sources for automated report assembly.
- You sell software that enhances in-silico prediction accuracy of antibody-target interactions before synthesis.
- You sell systems that standardize data capture and annotation for all experimental outputs during discovery phases.
- You sell solutions that track project-level expenditures against budget allocations for R&D initiatives.
- You sell platforms that enforce electronic record-keeping and signature protocols for clinical data operations.
Deprioritize if:
- Your solution does not address any of the specific breakdowns within clinical data management, R&D, or regulatory compliance.
- Your product is limited to basic functionality without specialized features for biotechnology or clinical trials.
- Your offering is not built for complex, multi-system environments involving outsourced research partners.
Who Can Sell to Shattuck Labs Right Now
Clinical Data Management Platforms
Medidata Rave Clinical Cloud - This company offers an end-to-end platform for clinical trial data management and operations.
Why they are relevant: CRO eCRF design at Shattuck Labs may not consistently capture required data points for specific regulatory filings. Medidata Rave can enforce standardized eCRF templates and data capture rules during the initial design phase, preventing discrepancies before database build.
Veeva Clinical One Data Management - This company provides a modern cloud application for clinical data collection, cleaning, and reporting.
Why they are relevant: External laboratory data files at Shattuck Labs may contain inconsistent formatting that blocks automated ingestion into the clinical database. Veeva Clinical One can standardize external data file formats and enforce validation checks upon transfer, ensuring data readiness for integration.
Biologics Discovery and Design Platforms
Schrödinger - This company offers a physics-based computational platform for drug discovery and materials science.
Why they are relevant: Computational protein design models at Shattuck Labs sometimes predict antibody binding that fails in wet lab validation. Schrödinger’s platform can enhance the accuracy of in-silico prediction for antibody-target interactions, reducing the number of failed constructs in synthesis.
Benchling - This company provides a life science R&D cloud for managing biological data, experiments, and lab workflows.
Why they are relevant: Experimental data from early-stage screening systems at Shattuck Labs may not connect directly to protein design software for iterative optimization. Benchling can integrate diverse experimental data, link it to specific protein designs, and provide a centralized platform for iterative design cycles.
R&D Project and Portfolio Management Systems
Planisware - This company offers enterprise project portfolio management software tailored for R&D-intensive industries.
Why they are relevant: Budget allocations for R&D projects at Shattuck Labs may not update quickly after strategic pipeline refocus decisions. Planisware can provide dynamic budget adjustment capabilities linked to strategic portfolio changes, ensuring real-time alignment of resources.
Sciforma - This company delivers project and portfolio management software for managing complex R&D initiatives and resource planning.
Why they are relevant: Project tracking systems at Shattuck Labs may fail to provide granular cost data for specific preclinical activities. Sciforma can offer detailed cost tracking at the activity level within R&D projects, enabling accurate assessment of burn rates against budgets.
Final Take
Shattuck Labs is scaling its clinical development and advanced biologics engineering, leading to critical breakdowns in clinical data oversight and R&D portfolio optimization. Observable failures include data discrepancies between external sources and internal systems, as well as misaligned R&D spending. This account is a strong fit for vendors whose solutions specifically address clinical data integrity, precise biologics design validation, and real-time R&D financial management.
Identify buying signals from digital transformation at your target companies and find those already in-market.
Find the right contacts and use tailored messages to reach out with context.